Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

PROFISCOV (SinoVac Brazil), 2021 NCT04456595

CoronaVac (SinoVac) (n=6195) vs. placebo (n=6201)

randomized controlled trial   risk of bias NA

Studied treatment

CoronaVac
two doses of vaccine (3 μg in 0.5 mL) at day 0 and 14

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

16 centres, Brazil

Remark

very preliminary results from press release

Sinovac Turkish Trial, 0 NCT04582344

CoronaVac (SinoVac) (n=752) vs. placebo (n=570)

randomized controlled trial   risk of bias NA

Studied treatment

Control treatment

Patients

COVID-19 prophylaxis (excluding children)

Method

Remark

very preliminary results of a interim analysis

Xia (66), 2020 ChiCTR2000032459

Sinopharm Beijing (BBIBP-CorV) (n=-9) vs. placebo (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

China

phase 1/2

Remark

Sinopharm Wuhan Vero cell, 2021 NCT04510207

Sinopharm Wuhan (n=13765) vs. placebo (n=13765)

randomized controlled trial   risk of bias NA

Studied treatment

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

Remark

prespecified interim analysis